Trombonamo contains Eltrombopag Olamine, an oral thrombopoietin receptor agonist used to increase platelet production in patients with low platelet counts. It is primarily prescribed for chronic immune thrombocytopenia (ITP), thrombocytopenia due to hepatitis C infection, and severe aplastic anemia.

Mechanism of Action

• Eltrombopag binds to the thrombopoietin (TPO) receptor, c-Mpl, on megakaryocyte progenitor cells in the bone marrow.

• This stimulates proliferation and differentiation of megakaryocytes, leading to increased platelet production.

• It helps restore platelet counts, reducing the risk of bleeding in thrombocytopenic patients.

  Uses

  • Treatment of chronic immune thrombocytopenia (ITP) in patients unresponsive to standard therapies.

  • Management of thrombocytopenia in chronic hepatitis C infection to allow antiviral therapy.

  • Adjunct therapy in severe aplastic anemia to increase platelet counts.

  • Helps reduce bleeding risk in patients with low platelet levels.

    Adverse Effects

    • Headache

    • Nausea or vomiting

    • Fatigue or weakness

    • Increased liver enzymes